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DoxorubicinMultiple E2F1 phosphorylation sites have been described as targets of different kinases, yet their in vivo
implication is uncertain. We previously reported that GSK3β is able to phosphorylate E2F1 in vitro at Ser403
and Ser433. Recently, it has been shown that both residues are also direct targets of p38 MAP kinase. In order
to determine whether Ser403 phosphorylation occurs in vivo and to elucidate its role in E2F1 transcription
activity, we developed a phospho-E2F1(Ser403) antibody for use in in vivo detection studies. Our results
demonstrate that endogenous E2F1 is phosphorylated in vivo on Ser403, however neither GSK3β nor p38
MAP kinase are responsible for this event. E2F1 phosphorylation on Ser403 is induced after treatment with
doxorubicin in a dose response manner. The transcriptional response of E2F1 to doxorubicin is lower in an
E2F1 Ser/Ala403 mutated construct relative to the wild type, suggesting a role for Ser403 phosphorylation in
DNA damage conditions. Comparative study between the expression of the bcl2 gene family induced by the
wild type and E2F1 Ser/Ala403 mutant revealed a statistically different pattern between both conditions.
These results suggest that phosphorylation of Ser403 could inﬂuence the selection and regulation of E2F1
target genes.Biologia Molecular, Facultat de
E-08028 Barcelona, Catalunya,
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E2F family transcription factors have been recognized for their
ability to regulate cell cycle progression by coordinating a large group
of genes involved in G1 to S phase transition.Many recent studies have
shown that E2F activity could also promote the expression of genes
that control cell death, differentiation and development programs [1].
In mammals, the E2F family is compounded by 8 members; the
diversity in the E2F family reﬂects its different roles in transcriptional
regulation and cell function. E2F1-3, forming heterodimers with DP
proteins, are primarily transcriptional activators; in contrast, E2F-4-
8 principally act as transcriptional repressors. Among the eight
members of the E2F family described, E2F1 is unique in its ability to
induce apoptosis and autophagy [2,3].
E2F transcription activity is mainly regulated by members of the
Rb protein family. In quiescent cells, Rb proteins can bind to E2F and
“inhibit transcriptional activation” or, they can mediate the ‘active
repression’ of E2F-responsive genes by recruiting chromatin-remo-
delling factors including histone deacetylases. During G1-S transition,
pRb proteins are phosphorylated by cyclin-dependent kinase leading
its dissociation to E2F and activation of E2F by recruiting histone
acetylases [2].In addition to being regulated by the Rb family of proteins, E2F1
activity is also regulated by post-translational mechanism. For example,
DNA damage produces an increase in E2F1 protein by phosphorylation
of E2F1 on Ser31 and Ser364, a process catalysed by the kinases ATM
and Shk2, respectively. It has been suggested that these phosphoryla-
tions could increase E2F1 protein half-life by inhibiting its binding and
degradation through Skp2, and through disruption of the Mdm2/E2F1
interaction [4,5]. E2F1 phosphorylation on Ser332 and Ser337 was
also observed upon stimulation of serum-starved cells, a process in
which p34cdc2 kinase is implicated. The phosphorylation of E2F-1 on
Ser332 and Ser337 prevented its interaction with Rb and positively
regulated E2F1 transcriptional activity [6].
Although other phosphorylation sites of E2F1 have been described
as targets of different kinases, their implication in the phosphoryla-
tion in vivo is uncertain. We previously reported that GSK3β is able to
phosphorylate E2F1 in vitro at Ser403 and Ser433 [7]. Furthermore, a
functional interaction between both proteins was demonstrated,
showing that inhibition of GSK3β activity protected the cells from
apoptosis induced by over-expression of E2F1 [8,9]. However, despite
this data, phosphorylation of these residueswas not conﬁrmed in vivo.
Recent evidence indicates that both residues are also direct p38 MAP
kinase targets, and that these two amino acids are critical for the
modulation of E2F1 stability, sub-cellular localization and correct
execution of differentiation programs in keratinocytes [10]. E2F1
mutants lacking one or both of these residues cannot be exported
from the nucleus and degradedwhen keratinocytes are differentiating
[10].
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to perform due to the lack of a speciﬁc phospho-antibody against
these residues. In order to elucidate whether this phosphorylation
occurs in vivo and to study its role in E2F1 transcription activity, we
have developed a phospho-E2F1 antibody for use in in vivo detection
studies.
2. Materials and methods
2.1. Cell culture
U2OS and ER-E2F1 U2OS cells were cultured in DMEM media
containing 10% fetal calf serum. For ER-fusion proteins experiments,
cells were serum-starved overnight, prior to the addition of 400 nM
of 4-hydroxytamoxifen (Calbiochem, Germany) to activate E2F
nucleus translocation. For assays using inhibitors, cells were pre-
incubated for 1 h in serum-starved media in the presence of 10 μM
of SB216763 (Sigma-Aldrich, USA), 50 mM of LiCl (Merck, Germany),
5 μM Birb (a gift from Dr. Manel Joaquin), 10 μM of SB203580
(Calbiochem, Germany) or caffeine (Sigma-Aldrich, USA).
2.2. Plasmid constructs and transfections
[E2F]3-Luc and HA-E2F1 constructs were kindly provided by Dr. M.
Gstaiger (Friedrich-Miescher-Institut, Basel, Switzerland). Plasmid
pCMVHAER-E2F1 was kindly provided by Dr. Kristian Helin. GST-
E2F1 was kindly donated by Dr. E. Lam (Imperial Cancer Research,
London, UK). GST-hE2F1(AD), and mutated 403 and 433 forms were
kindly provided by Dr. Kouzarides (University of Cambridge, UK). ER-
E2F1 Ser/Ala 403 constructwas obtained by removing the E2F1 coding
region of pCMVHAER-E2F1 plasmid and replacing it with the E2F1
mutated coding region obtained by PCR ampliﬁcation of GST-hE2F1
(AD) plasmid using the Bam H1 restriction site. pcDNA-GSK3
constructs were previously generated in our laboratory as described
[7]. Bacterially expressed proteinswere produced in E. coli and isolated
using standard GST fusion protein protocols (Pharmacia, Sweden).
Luciferase activity was measured using the Luciferase Assay kit in
accordance with the manufacturer's recommendations (Promega,
USA).
Plasmids were transfected with Lipofectamin (Invitrogen, USA) in
accordance with the manufacturer's instructions. GSK3β siRNA was
generated and transfected as described [7]. In order to obtain the ER-
E2F1 Ser/Ala 403 U2OS stable cell lines, cells were re-suspended and
incubated in D-MEM selective medium, containing 10% serum and
750 μg/ml Geneticin Selective Antibiotic (G418) (Gibco, UK). After
15 days, the transfected stable cell line was obtained and maintained
in the D-MEM selective medium.
2.3. Western Blotting
Cells were washed and harvested with PBS. Cell pellets were re-
suspended and incubated for 30 min at 4 °C in lysis buffer (20 mM
Tris–HCl pH 8.0, 10 mM EDTA, 2.5 mM MgCl2, 1% Triton X100 with a
supplement 1/100 dilution of phosphatase and protease inhibitor
cocktail (Sigma-Aldrich, USA). Equal amounts of protein lysate were
subjected to 10% sodium dodecylsulphate polyacrylamide gel elec-
trophoresis and electrophoretically transferred to PVDF membranes.
The membranes were then blocked with 5% non-fat milk and 3%
BSA solution in PBS-T (PBS with 0.1% Tween 20) for 1h at room
temperature and immunoblotted. Antibodies that were used were as
follows: anti-phospho-E2F1 (Ser403) generated in our laboratory,
-actin, -E2F1, (Santa Cruz Biotechnology, USA), GSK3β and β-catenin
(BD Transduction Laboratory, USA), p38 MAP Kinase (Cell Signaling,
USA) and hemagglutinin epitope (Roche Diagnostics, Germany).
Primary antibody and secondary horseradish peroxidase-conjugated
antibody incubations were performed in 5% non-fat milk and 5%BSA solution in PBS-T. Blots were developed using an Enhanced
Chemiluminescence kit (Amersham, UK).
2.4. Generation of the speciﬁc phospho-E2F1 (Ser403) antibody
The antibody against phopho-E2F1 Ser403was generated upon our
request (Sigma, USA). Shortly afterwards, phospho-peptide was
conjugated with keyhole limpet hemocyanin and used as the antigen.
Antibody was raised in rabbits against synthetic phospho-peptide by
6 immunisations per animal and 5 bleeds. ELISA analysis was per-
formed using the phospho-antibody, by which result, we selected 5
that showed the highest titer. Puriﬁcationwas done by afﬁnity column
to which the non-phosphorylated peptide was attached, in order to
remove antibodies to epitopes outside the phosphorylation domain.
Antibody was selected by measuring its speciﬁc immuno-reactivity
against a recombinant E2F1, phosphorylated in vitro by GSK3β.
2.5. In vitro kinase assay
Puriﬁed GST-E2F1 protein was incubated with 200 μM ATP in a
buffer containing 20 mM Tris–Cl (pH=7.5), 10 mM, MgCl2 and 5 mM
DTT in the presence of puriﬁed GSK3β ( 60 μM) (Sigma-Aldrich, USA),
for 90 min. The reaction products were resolved in sodium 15% SDS-
PAGE, and the phosphorylated proteins were visualized through
Western Blot analysis.
2.6. Multiplex ligation-dependent probe ampliﬁcation
Total RNA was prepared using Ultraspec RNA isolation system
according to the manufacturer's recommendations (BIOTECX, USA).
cDNA was synthesised through incubation with the MMLV-RT
enzyme for 15 min at 37C and inactivation of MMLV-RT enzyme
was carried out prior to MLPA ampliﬁcation. DNA was analyzed by
MLPA using a SALSA MLPA R011-B1 Apoptosis mRNA probe kit as
previously described (MRC Holland, The Netherlands) [11]. The
resulting PCR fragments were separated by capillary electrophoresis
on a 48-capillary ABI-Prism 3730 Genetic Analyzer (Applied Biosys-
tems/Hitachi, Foster City, CA). Peak area and height were measured
using GeneScan analysis software (Applied Biosystems). Data was
analyzed with Coffalyser Software (MRCHolland).
2.7. Statistic analysis
Data was analysed with GraphPad Prism4 software. Results are
presented as Mean±S.E.M. for n=4. Experimental data sets were
comparedby a two-sampled, two-tailed and unequal S.D. Student t Test.
Values of *Pb0.05, **Pb0.01 and ***Pb0.001 were considered statisti-
cally signiﬁcant. All the experiments were performed at least three
times.
3. Results
3.1. Characterization of a speciﬁc phospho-E2F1 (Ser403) antibody
In order to study the in vivo role of E2F1phosphorylation on Ser403,
we have developed a phospho-speciﬁc antibody suitable for immu-
nodetection experiments. The antibody was directed against a
phospho-peptide sequence around Ser403; this sequence was con-
served in human, mouse and rat species (Fig. 1A). To validate the
speciﬁcity of the antibody, we studied its immunoreactivity against a
recombinant E2F1 phosphorylated in vitro by GSK3β. We selected an
antibody set that fully reacts against phospho-E2F1 butmuch lesswith
the unphosphorylated form (Fig. 1B). Addition of increasing concen-
trations of peptide that included Ser-403 or the in vitro kinase reaction
mix, produced a decrease in phospho-E2F1 immunoreactivity
(Fig. 1C). Physical interaction between E2F1 and GSK3β is described
Fig. 1. Establishment and characterization of the phospho-speciﬁc E2F1(Ser403) antibody. A) Phospho-peptide sequence used for the generation of phospho-speciﬁc E2F1(Ser403)
antibody is shown. B) 5 ng of GST-E2F1 was phosphorylated in vitro with GSK3β (+) and phosphorylated (p-E2F1) and total E2F1 expression were determined by Western Blot
analysis. C) 5 ng of GST-E2F1 was phosphorylated in vitro with GSK3β in the absence or in the presence of 1 ng/ml, 2 ng/ml, 50 ng/ml and 1 μg/ml un-phosphorylated peptide
described in A. Phosphorylated (p-E2F1) and total E2F1 expressions were determined by Western Blot analysis. D) In vitro kinase assay was performed as described in B, in the
presence or in the absence of the indicated reagents, and phosphorylated (p-E2F1) and total E2F1 expressions were determined by Western Blot analysis. E) 5 ng of GST-E2F1 was
phosphorylated in vitrowith GSK3β (+) or not (−) andWestern Blot analysis was performed using total E2F1 antibody and, phospho-speciﬁc E2F1 antibody (p-E2F1). Hybridization
with phospho-speciﬁc E2F1 antibody was achieved in absence or presence of 1 ng/ml, 50 ng/ml and 1 μg/ml unphosphorylated or phosphorylated peptide in the mixture blot as
indicated on Figure.
Fig. 2. E2F1 Ser403 phosphorylation in vivo. A) Cell extracts from stable U2OS cells
transfected with wild type ER-E2F1 (Wt), Ser/Ala 403 (Ala) and Ser/Asp 403 (Asp) ER-
E2F1 mutants were obtained and phosphorylated (p-ER-E2F1) and total ER-E2F1
expressions were assessed by Western Blot analysis. B) Phosphorylated (p-E2F1) and
total E2F1 expressions were determined by Western Blot analysis from 20 μg of U2OS
cell extract and from 5 ng of GST-E2F1 phosphoryated or not in vitro by GSK3β. Samples
were loaded in the same gel. The ﬁlm exposure time for E2F1 high exposure was 2 min
and for E2F1 low exposure was 5 s.
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a phosphorylation event and not a conformational change, we studied
the immunoreactivity of the antibody in conditions where GSK3β
activity was blocked. The lack of ATP in the incubation kinase mix
produced a total absence of immunoreaction (Fig. 1D). Similarly,
inhibition of GSK3β activity through the addition of its speciﬁc
inhibitor SB 216763 totally abolished the immunoreaction signal. The
speciﬁcity of the phospho-E2F1 (Ser403) antibodywas also studied by
measuring its immunoreactivity on Western Blot in the presence of
excess phosphorylated and unphosphorylated peptide in the immu-
noreaction mixture, together with speciﬁc phospho-E2F1 (Ser403)
antibody. The presence of phosphorylated peptide totally abrogated
the detection of phospho-E2F1. In contrast, the addition of unpho-
sphorylated peptide did not produce any change on the immunoreac-
tivity of the antibody, conﬁrming its high speciﬁcity (Fig. 1E). From
these results we concluded that the antibody obtained speciﬁcally
detects the phosphorylated form of E2F1 at Ser403.
3.2. In vivo study of E2F1 Ser403 phosphorylation
In vivo studieswere performedusing the antibody described above.
In order to demonstrate whether E2F1 Ser403 phosphorylation occurs
in vivo, U2OS cells were transfected with wild type, and Ser403 ER-
E2F1 mutants expression vectors and detection of phosphorylation
form was determined by Western Blot analysis using the phospho-
speciﬁc antibody [12].Immunoreaction was obtained in cells trans-
fectedwithwild type E2F1; in contrast, transfectionwith E2F1 Ser/Ala
and Asp 403 mutants did not show phosphorylation (Fig. 2A). This
result demonstrates that onlywild type E2F1 is indeedphosphorylated
in vivo Phosphorylation state of E2F1 at Ser 403 was also determined
on the endogenous E2F1 protein. Immunoreaction against the speciﬁc
phospho-E2F1 antibody was analyzed in U2OS cell extract. Immuno-
reactivity of the endogenous protein was detected in the same rate
of intensity as those detected on the recombinant E2F1 (Fig. 2B).
However the total E2F1 protein was much less in the cell extract thanon the recombinant (Fig. 2B). These results suggest that E2F1 is highly
phosphorylated at Ser403 in vivo.
Several studies have demonstrated that E2F-1 activity is regulated
by phosphorylation during DNA damage [4,5]. In order to study
whether phosphorylation of Ser403 is involved in this process, we
analyzed the effect of doxorubicin on this phosphorylation. Doxorubicin
is an intercalating DNA agent and produces activation of the DNA
Fig. 3. Effect of doxorubicin and caffeine on the E2F1 Ser403 phosphorylation in vivo. A) Stable U2OS ER-E2F1 cells were treated for the indicated hours with doxorubicin (dox), and
analysis of the phosphorylated (p-ER-E2F1) and total ER-E2F1 expression was assessed by Western Blot in total cell lysates. B) U2OS ER-E2F1 cells were treated overnight with the
indicated concentrations of caffeine, in the presence or absence of 1.6 μM of doxorubicin and analysis of the phosphorylated (p-ER-E2F1), total ER-E2F1, and actin expression was
assessed byWestern Blot in total cell lysates. C) Stable U2OS ER-E2F1 cells were treated for the indicated hours with 1.6 μMof doxorubicin (dox), and analysis of the phosphorylated
(p-E2F1), total E2F1, actin and p53 expression were assessed by Western Blot in total cell lysates.
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activity [13]. The U2OS ER-E2F1 stable cell line was treated with
doxorubicin and determined the phosphorylation state of Ser403 at
different incubation times. Phosphorylation of E2F1 on Ser403 was
detected after 12h of treatment; a higher dose of doxorubicin produced
a higher phosphorylation of E2F1 (Fig. 3A). Cells respond to doxorubicin
by activating the ataxia-telangiectasia mutated (ATM) kinase [14]. In
order to investigate whether the ATM pathway is involved in the
phosphorylation of E2F1 on Ser 403we analyzed the effect of caffeine, a
potent inhibitor of ATM kinase, in this phosphorylation [16]. The
presence of caffeine does not produce any change in the Ser403
phosphorylation state after the doxorubicin treatment, which indicates
that this kinase is not responsible for this phosphorylation (Fig. 3B). The
effect of doxorubicin was also investigated on the endogenous E2F1
protein. Doxorubicin treatment induced a slight increase of phosphor-
ylation of E2F1 on Ser403, which was more evident at 24 h after
the treatment (Fig. 3C).
3.3. Role of GSK3β and p38 MAP Kinase on E2F1 Phosphorylation at Ser
403 in vivo
Previous results indicated that Ser403 could be a target of GSK3β
[7,9]. In order to determine whether this kinase is responsible for in
vivo phosphorylation of E2F1, we investigated the effect of inhibition
of GSK3β activity on the endogenous phosphorylation state of E2F1.
To this end, we used SB216762, an ATP-competitive inhibitor of
GSK3β activity, and LiCl, which promotes the phosphorylation and
inactivation of GSK3β at Ser 9 [15,17]. Results showed that neither
SB216762, or LiCl, were able to decrease the basal E2F1 Ser403Fig. 4. Role of GSK3β on the E2F1 Ser403 phosphorylation in vivo. U2OS cells were treated
for the indicated time with SB216763 and LiCl, and detection of the indicated proteins
expression was determined by Western Blot analysis in the total cell extract.phosphorylation state, suggesting that GSK3β does not participate in
this process (Fig. 4). The levels of β-catenin, a well known substrate of
GSK3 β increased after the treatment of inhibitors conﬁrming that
GSK3β activity was indeed inhibited (Fig. 4) [18]. From these results
we can conclude that although GSK3β is capable of phosphorylating
E2F1 at Ser403 in vitro, this process does not occur in an in vivo
situation.
In addition to GSK3β, it has recently been suggested that p38 MAP
kinase could also phosphorylate E2F1 at Ser403 during keratinocyte
differentiation [10]. We were also interested in studying whether p38
MAP kinase is involved on the endogenous phosphorylation state of
E2F1 at Ser403. Incubation of U2OS cells with SB 203580 and Birb, a
speciﬁc inhibitors of p38 kinase, did not affect neither the phosphor-
ylation of E2F1 nor total E2F1 protein levels (Fig. 5A) [19,20]. TheFig. 5. Role of p38MAP kinase on the E2F1 Ser403 phosphorylation in vivo. U2OS cells were
treated for 12 h with Birb and SB203580 as described in Materials and methods and
detection of the indicated proteins expression was determined byWestern Blot analysis
in the total cell extract. B) U2OS cells were transient transfected with the indicated
expression vectors and protein extract were obtained 24 h after transfection. Detection
of the indicated proteins was achieved by Western Blot analysis.
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expression of phospho-HSP27, a substrate of p38 MAP kinase ) [21].
No change on E2F1 phosphorylation at Ser 403 was also found in cells
transient transfectedwith bothMKK6 and p38MAP kinase expression
plasmids. (Fig. 5B). From these results we can conclude that p38
MAPK is not involved in the phosphorylation of E2F1 at Ser403 in vivo
on U2OS cells.
3.4. Role of Ser403 in E2F1 transcription activity
In order to address the role of E2F1 phosphorylation at Ser403 in
the transcription function of E2F1, we measured E2F transcription
activity after doxorubicin treatment. As demonstrated above, this
agent is capable of phosphorylating E2F1 on Ser403. Stable cell lines
over-expressing the ER-E2F1 wild type and ER-E2F Ser/Ala 403
mutant were transfected with luciferase reporter vector under the
control of three E2F sequences, and luciferase activity was measured
after 24 h of OHT addition. Translocation of wild type ER-E2F1 to the
nucleus produced an induction of E2F1 transcriptional activity similar
to the mutated form (Fig. 6A). However, when E2F1 translocation was
achieved in the presence of doxorubicin, the ER-E2F1 Ser/Ala 403
construct showed less luciferase activity when compared with the
wild type (Fig. 6A). These results strongly suggest that phosphoryla-
tion of E2F1 on Ser403 could play a role in the regulation of E2F1
transcription activity during DNA damage stress. It is interesting to
note that wild type and ER-E2F1 mutants are expressed at similar
levels, excluding the possibility that the differences found in
transcription activity were due to the effect of efﬁcient on transfection
(Fig. 6B).
Phosphorylation of Ser403 could inﬂuence not only the extent of
the transcription response, but also the selective regulation of E2F1Fig. 6. Role of Ser403 phosphorylation on the transcription activity of E2F1. A) Stable U2OS
ER-E2F1 (E2F1 Wt) and U2OS ER-E2F1 Ser/Ala 403 mutant (E2F1 Ala) cells were
transfected with [E2F]3-Luc vector and treated with and without 1.6 μM of doxorubicin
for 16 h. As indicated, OHT was added to the cell for 8 h and luciferase activity was
measured for all the conditions. In each set of transfection, luciferase activity was
normalized by the results obtained in untreated cells. Statistically signiﬁcant
differences were obtained by comparison with cells transfected with ER-E2F1 (Wt).
B) Detection of the phosphorylated (p-ER-E2F1) and total ER-E2F1 expression were
determined by Western Blot analysis in the total cell extract.target genes. In order to study this possibility, we determined the
apoptotic gene expression pattern in cells over-expressing ER-E2F1
wild type and mutant constructs. The effect of E2F1 phosphorylation
on Ser403 in the expression of apoptotic genes was measured using a
RT-Multiplex Ligation-dependent Probe Ampliﬁcation analysis (RT-
MLPA). This method enabled us to analyze the expression of 43
apoptotic genes in a single experiment. RT-MLPA analysis showed
that both E2F1 wild type and E2F1 Ser/Ala403 mutant are capable of
regulating the expression of several apoptotic genes (Fig. 7). Some of
them: BIM, PUMA, NOXA, Hrk/Dp5, APAF and Smac/DIABLO have
previously been reported to be targets of E2E1; others: bcl2, MOAP
and Bik are new targets [22–24]. A comparative study between E2F1-
regulated genes induced by wild type and mutant over-expression
reveals a statistically different pattern (more signiﬁcant with HRK and
BAK1, and less signiﬁcant with BOK, MOAP1 XIAP and p21) between
the two conditions. Note that protein levels of stable transfected E2F1
wild type and E2F1 Ser/Ala403 mutant are the same, excluding the
possibility that the differential responses were due to the levels of
protein (Fig. 6B). These results suggest that phosphorylation of Ser403
could inﬂuence the selection and regulation of E2F1 target genes.
4. Discussion
Growth factors, adhesion and apoptosis inductors modulate E2F1
activity through a complex system of signal transduction pathways
that commits cells to proliferation or apoptosis. In accordance with
this essential role in cell fate, E2F1 transcriptional activity is tightly
regulated by distinct mechanisms. During cell proliferation, E2F1's
ability to regulate transcription is controlled through its association
with the retinoblastoma family of proteins. E2F1 activity is also
regulated by post-translational mechanisms, such as phosphorylation
and/or acetylation. The aim of this work is to investigate whether
phosphorylation of E2F1 at Ser403 occurs in vivo and to determine its
participation in E2F1 transcriptional activity.
The availability of the antibody rosed against synthetic phopho-
E2F1 Ser403 peptide allowed us to re-investigate the presence of this
phosphorylation in vivo. Several previous studies had demonstrated
that GSK3β, p38 MAP kinase and cdk7 were able to phosphorylate
in vitro E2F1 at Ser403. [7,10,25]. Recently, it has been reported
that Ser403 is an in vivo target of p38 MAP kinase in differentiated
keratinocytes [10].This suggestion was based on a different mobility
pattern that was observed between the phospho- and unphospho-
E2F1. By using the speciﬁc phospho-E2F1 antibody characterized in
this study we demonstrate that E2F1 is phosphorylated in vivo either
on over-expressed or endogenous E2F1 protein. Phosphorylation was
detected on ER-E2F1 transfected cells in absence of OHT, condition in
which the fusion protein is localized on the cytosol, as well as on the
endogenous nuclear E2F1 protein. A simple interpretation would be
that the kinase responsible for this phosphorylation is localized in
both cellular compartments. However, other possibilities should be
taken in consideration. For example, E2F1 was phosphorylated on the
cytosol and then translocated to the nucleus.
p38 MAP kinase was not able to phosphorylate endogenous E2F1
at Ser 403 in vivo. In contrast with these results, in vivo phosphor-
ylation of E2F1 at Ser403was detected in differentiated keratinocytes;
this phosphorylation induces E2F1 export from the nucleus and
degradation [10]. It appears that the contribution of p38 MAP kinase
to Ser403 phosphorylation is context- and cell type-dependent.
GSK3β has also been identiﬁed as a kinase capable of phosphor-
ylating E2F1 at Ser403 in vitro. Several studies have also demonstrated
that both proteins can interact in vivo [7,8]. Furthermore, functional
relations have been found during the apoptosis and neuronal cell
differentiation [8,9]. Apoptosis function of E2F1 requires GSK3β
activity and association of GSK3β to E2F1 facilitates NGF differen-
tiation. Although the indirect data presented in these studies
suggested that GSK3β was not able to phosphorylate E2F1 in vivo,
Fig. 7. RT-MLPA analysis. Stable U2OS ER-E2F1 (E2F1Wt) and U2OS ER-E2F1 Ser/Ala 403mutant (E2F1 Ala) cells were treated with or without OHT for 8 h and RT-MLPA analysis was
achieved as described in Materials and methods. Values are obtained by normalizing the DNA ampliﬁcations results to condition without OHT.
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study we demonstrated that GSK3β is not directly involved in the
phosphorylation of E2F1 in vivo. Our ﬁnding is in concordance with
previous reports demonstrating that the effect of GSK3β on E2F1
transcriptional activity and on the stabilization of the E2F1 protein
was also found in a kinase-defected mutant [7,9].
The question of which kinase is responsible for phosphorylation at
Ser403 is still open. It is possible that the kinase involved in the
phosphorylation of this residue was different depending on the cell
type. According to this idea, p38 MAP kinase would be the major
contributor on the phosphorylation status of E2F1 in keratimocytes
and, in contrast, GSK3β and Cdk7 could have a role on phosphorylation
in HEK234 and Hela cells respectively [7,10,25]. Our studies on U2OS
cells exclude the involvement of p38 MAP kinase, or GSK3β in this
process. However, we should be aware that the studies tomeasure the
in vivo phosphorylation have been performed using different
approaches and this might inﬂuence the results. Endogenous E2F1
showed high levels of phosphorylation in basal conditions and it
would be possible that, in most of the cell conditions, once E2F1 is
translated becomes totally phosphorylated. Works are in progress in
our lab to identify the kinase responsible for the phosphorylation at Ser
403. From these ongoing investigations, we ruled out the participation
of cdk7 (data not shown).We also excluded the involvement of cdk8, a
kinase that has been reported to phosphorylate the transactivation
domain of E2F1, domain where Ser 403 is localized (data not shown)
[26]. It may be possible that a constitutive active kinase was the
responsible for this phosphorylation.
In this study we show for the ﬁrst time that DNA damage induces
the phosphorylation of E2F1 on Ser403. Previous works have
implicated phosphorylation of E2F1 on Ser31 and Ser 364 in the
regulation of E2F1 activity in response to DNA lesions [4,5]. These
phosphorylations caused the stabilization of E2F1 protein by
disruption of the Mdm2/E2F1 interactions [4]. We believe that both
events could act complementarily to regulate E2F1 transcriptionactivity. In this respect, we have demonstrated that the transcriptional
response of E2F1 to doxorubicin is lower in a E2F1 Ser/Ala403
mutated construct than in the wild type. It is possible that while the
function of Ser364 phosphorylation is to enhance E2F1 stability
phosphorylation of Ser403 acts by regulating transcription efﬁciency
DNA damage also regulates E2F1 activity by stabilizing E2F1 protein
through interaction with 14-3-3τ protein and preventing E2F1
ubiquitination [27]. It could be possible that phosphorylation of E2F
at Ser 403 could modulate this interaction and, by this mechanism,
regulates E2F1 activity. Moreover, Ser 403 phosphorylation could
inﬂuence the E2F1 transcription activity by interfering the interaction
of 14-3-3ε with E2F1, which has been reported to occur in the
promoter of some E2F1 target genes [28].
As ATM is one of the kinases responsible for doxorubicin action,
and as it has been demonstrated that this kinase is responsible for the
phosphorylation of E2F1 on Ser364, we investigated whether this
kinase is also involved in E2F1 Ser403 phosphorylation [4,15]. In
contrast to the phosphorylation of Ser364, ATM is not involved in
Ser403 phosphorylation. Cells respond to doxorubicin, not only
activating the ATM pathway but also leading to the regulation of
others pathways including the generation of reactive oxygen species
[29]. This work opens the door to very interesting investigations that
will determine the kinase responsible for the phosphorylation of
Ser403 in response to DNA damage.
In vivo expression of E2F1-regulated genes depends on speciﬁc
E2F1 box domains and cell context. In this respect, post-transduction
modiﬁcation of E2F1 protein appears essential for the selection of
E2F1 target genes. For example, acetylation of E2F1 selectively
activates APAF, an apoptotic target of E2F1, but not DHFR, a
proliferative target [30]. We were interested in discovering whether
phosphorylation of E2F1 on Ser403 could also inﬂuence the selection
in the expression of E2F1-regulated genes. Our results demonstrate
that over-expression of wild type and mutated E2F1 induces a slightly
different pattern in the Bcl2 gene family. Compared with the wild
918 S. Real et al. / Biochimica et Biophysica Acta 1803 (2010) 912–918type, E2F1 Ser403 mutation causes a decrease in transcription in BiK,
HRK and MOAP mRNA levels; and an increase on BOK, XIAP and p21.
These results suggest that Ser403 phosphorylation could selectively
modulate the expression of E2F1 target genes. It is worth noting that
RT-MLPA analysis detected the changes on the E2F1-regulated gene
previously reported by others (HRK, PUMA, APAF1, FLIP and NAIP)
[22–24]. Ser403 is localized in the transactivation domain of E2F1.
Consistent with this fact, it is very likely that phosphorylation of this
residue could inﬂuence the ability of E2F1 to recruit E2F1-interacting
proteins that are key in the selective regulation of E2F1 targets.
In summary, we demonstrate that E2F1 is phosphorylated in vivo
on Ser403. This phosphorylation could selectively modulate the
expression of E2F1 target genes. Neither GSK3β nor p38 MAP kinase
that are shown to in vitro phosphorylate E2F1 on Ser403, are involved
in this phosphorylation. In this study we demonstrated for the ﬁrst
time that DNAdamage induces the phosphorylation of E2F1 on Ser403.
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